Skip to main content

Table 1 Scores prior to autologous hematopoietic stem cell transplantation

From: Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease

Patient# HBI CSI Montreal CDEIS SES-CD Rutgeerts CDAI
1 37 30 A2 L4 B2 17 18 i4 450.5
2 18 22 A3 L3 B2 6 8 247
3 22 20 A1 L3 B1 11 14 306
4 48 35 A1 L1 B1 427
5 15 28 A2 L3 B2 1 4 240
6 14 23 A2 L3 B1 7 6 i4 250
7 15 32 A2 L3 B1p 15 22 261
8 14 20 A2 L3 B2 14 14 i4 273.7
9 21 31 A3 L3 B3p 308
10 22 28 A3 L3 B3p 8 7 i4 260
11 16 16 A2 L3 B2 10 13 i4 284.8
12 13 36 A2 L3 B2P 36 24 i4 287.5
13 14 34 A2 L3 B2 34 11 i4 186
14 11 17 A1 L3 B2P 155
Mean ± SD 20 ± 10.3 26.5 ± 6.8   14.5 ± 11.1 12.8 ± 6.5   281.2
  1. HBI Harvey–Bradshaw index; CSI Crohn’s severity index; CDEIS Crohn’s disease endoscopic index of severity; SES-CD simple endoscopic score for Crohn’s disease; CDAI Crohn’s disease activity index; SD standard deviation
\